Financial Reports Latest Updates Industry Maps Economic Calendar

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Annual Reports

Q: Where can I read IOVANCE BIOTHERAPEUTICS, INC. (IOVA) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

IOVANCE BIOTHERAPEUTICS, INC. is listed on Nasdaq, classified by the SEC under Biological Products, (No Diagnostic Substances) (SIC 2836). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1425205 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$99.3M	$60.0M	+65.7%
Operating income	$-51.9M	$-113.8M	+54.4%
Net income	$-47.3M	$-111.7M	+57.6%
EPS (diluted)	$-0.11	$-0.33	+66.7%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 99.3 mn Net income -47.3 mn

Show table：Income statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0	0	0	0	0	0	0	0	0	—	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.24	0.47	0.48	0.72	31.1	58.6	73.7	49.3	60.0	67.5	86.8	71.4	99.3
Operating income	-0.02	-0.08	-0.17	-0.5	-0.66	-10.6	-5.81	-4.18	-3.14	-1.65	-1.63	-1.72	-0.7	-1.03	-9.41	-11.5	-2.26	-2.11	-2.80	-4.87	-5.30	-6.44	-7.64	-8.45	-7.01	-11.7	-19.0	-15.9	-20.9	-23.6	-22.3	-26.1	-26.9	-31.4	-35.1	-34.9	-40.0	-50.2	-51.6	-65.1	-70.8	-63.6	-59.0	-68.5	-75.6	-81.4	-86.2	-99.5	-91.7	-99.7	-100	-107	-111	-110	-118	-121	-118	-102	-89.1	-86.6	-121	-114	-94.9	-73.5	-81.0	-51.9
Net income	-0.02	-0.08	-0.71	-0.74	-0.56	-11.0	-5.82	-8.35	-5.77	-0.33	-0.67	3.47	-1.05	-3.43	-9.41	-11.5	-2.26	-2.11	-2.80	-4.65	-5.30	-6.37	-7.63	-8.36	-6.88	-11.6	-18.8	-15.7	-20.7	-23.4	-22.1	-25.9	-26.5	-30.7	-33.8	-32.6	-37.0	-47.5	-49.5	-63.6	-69.6	-63.0	-58.6	-68.4	-75.5	-81.3	-86.1	-99.3	-91.6	-99.3	-99.6	-105	-107	-107	-114	-116	-113	-97.1	-83.5	-78.6	-116	-112	-91.3	-71.9	-79.0	-47.3

Balance sheet

Quarterly · In mn (USD)

Total assets 916 mn Total liabilities 179 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	1.30	—	0.33	3.30	0.52	0.03	0.02	0.01	0.01	0.01	0.58	0.14	19.9	18.1	18.5	17.2	45.0	111	113	110	104	99.4	192	181	170	153	135	171	149	303	280	266	475	445	411	367	316	256	783	724	636	605	667	583	508	490	432	370	479	638	275	383	308	386	482	499	457	513	423	429	443	467	464
Total assets	—	—	—	1.46	—	0.47	3.44	0.57	0.08	0.07	0.03	0.03	0.03	0.6	0.17	19.9	18.1	18.5	17.4	46.5	114	115	112	106	101	194	182	172	155	138	174	155	307	285	271	481	462	436	396	345	288	818	782	768	751	853	829	777	701	611	546	664	825	757	852	780	870	964	991	910	967	907	905	913	926	916
Current liabilities	—	—	—	0.82	—	1.87	9.13	13.3	17.3	16.7	16.6	11.3	12.3	3.37	3.51	2.27	1.11	1.16	1.26	1.66	1.91	1.87	2.86	1.63	1.83	4.61	3.19	4.97	5.50	8.86	8.53	9.89	14.7	14.2	16.7	14.4	22.1	33.8	34.6	39.1	39.5	54.9	64.4	54.9	55.1	60.5	64.8	89.2	77.1	64.2	79.3	91.5	87.3	88.6	91.0	110	83.2	93.6	118	122	123	129	126	138	129	107
Total liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	9.89	—	—	—	14.6	26.6	38.5	40.7	45.7	45.0	59.3	70.5	112	103	108	131	156	149	138	152	164	158	179	178	196	190	196	218	200	199	209	203	215	204	179
Equity	-0.01	—	—	0.64	—	-1.40	-5.69	-12.8	-17.3	-16.6	-16.6	-11.3	-12.3	-2.77	-3.34	17.6	16.8	17.4	16.2	44.9	112	113	109	104	98.9	189	179	167	150	129	165	145	293	271	254	466	435	397	355	299	243	758	712	657	647	744	698	622	552	473	394	500	667	579	674	585	680	769	773	710	768	698	702	699	722	736

Cash flow

Quarterly · In mn (USD)

Operating -60.8 mn Investing -74.0 mn Financing 49.3 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-0.01	-0.14	-0.11	-0.37	-0.56	-1.27	-1.65	-2.71	-0.76	-1.20	-0.28	-0.3	-0.68	-0.43	-2.25	-2.27	-1.32	-1.73	13.9	3.46	-11.4	-3.84	-6.58	-4.55	-3.75	-12.2	-12.2	-18.8	-17.5	-21.4	-21.0	-17.9	-23.9	-27.9	-31.6	-29.1	-33.8	-42.2	-53.8	-65.3	-36.6	-40.5	-62.7	-62.4	-54.0	-57.7	-53.9	-73.8	-77.6	-63.6	-77.7	-99.8	-94.0	-84.1	-84.0	-122	-98.4	-59.0	-73.3	-104	-67.5	-78.7	-52.6	-72.1	-60.8
Investing	0	0	0	0	-0.05	0.03	0	-0.06	0	0	0	0	0	-0.01	0	0	0	-0.16	-1.43	-0.78	-99.9	-0.21	29.7	-0.15	-0.17	-16.6	25.8	18.8	25.3	14.5	0.06	-0.02	-30.5	-149	-206	1.03	58.7	3.50	26.8	100	-424	-53.0	58.8	77.2	-159	12.8	69.3	86.5	95.8	73.7	0.46	153	-157	-79.0	-72.8	-112	40.2	-48.8	23.7	15.9	13.8	17.0	0.78	11.4	-74.0
Financing	0.02	0.34	0.7	0.86	0.05	0.78	2.30	2.37	0.25	1.22	0.27	0.3	1.25	0	21.8	0.54	1.82	0.64	32.5	70.6	5.67	1.71	0.28	0	96.2	0.49	0.22	0.38	-0.65	56.0	2.90	170	3.36	12.0	239	0	3.38	0.66	2.09	3.83	568	1.17	2.96	50.4	164	20.8	4.15	1.42	-2.07	0.23	191	258	1.02	203	0.96	194	153	42.0	2.31	143	13.2	88.1	56.2	94.3	49.3
Cash at period end	0.01	0.21	0.8	1.29	0.72	0.27	0.91	0.51	0	0.02	0	0	0.57	0.13	19.7	17.9	18.4	17.2	44.9	111	12.6	10.2	13.6	8.94	101	92.9	107	107	114	163	145	297	246	80.7	82.2	54.1	76.9	38.9	14.0	52.5	161	68.3	67.3	132	82.8	58.6	78.2	92.4	108	118	232	543	230	268	115	134	229	164	116	172	132	158	163	197	111

Profitability

Quarterly · %

Operating margin -52.3% Net margin -47.6%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-46254.6%	-25236.9%	-25156.8%	-16464.6%	-327.6%	-152.1%	-117.5%	-245.8%	-189.8%	-140.7%	-84.7%	-113.5%	-52.3%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-44759.7%	-24255.9%	-24145.0%	-15800.8%	-312.2%	-142.7%	-106.6%	-235.5%	-186.3%	-135.3%	-82.9%	-110.7%	-47.6%

Returns & leverage

Quarterly · %

ROE -40.4% ROA -31.8% Debt ratio 19.6%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	-243.9%	—	—	—	—	—	—	—	—	—	—	—	-807.8%	-1174.8%	-346.1%	-291.2%	-37.9%	-23.1%	-29.4%	-38.2%	-37.2%	-27.8%	-22.8%	-31.6%	-39.0%	-53.6%	-49.4%	-47.5%	-58.9%	-44.3%	-52.6%	-55.7%	-40.4%	-36.8%	-45.2%	-54.7%	-51.6%	-67.9%	-42.5%	-47.8%	-54.3%	-59.6%	-37.8%	-44.1%	-53.5%	-59.8%	-61.9%	-71.4%	-70.6%	-67.5%	-79.7%	-81.1%	-81.9%	-66.8%	-65.4%	-56.6%	-57.5%	-51.9%	-53.2%	-53.9%	-55.5%	-47.5%	-40.4%
ROA	—	—	—	-106.5%	—	-2784.3%	-525.9%	-2532.2%	-40213.0%	-7623.5%	-872.5%	-1106.5%	2697.3%	-507.6%	-10560.2%	-255.1%	-293.7%	-264.2%	-212.3%	-35.6%	-22.6%	-28.7%	-37.0%	-36.4%	-27.3%	-22.3%	-30.9%	-38.1%	-52.1%	-47.4%	-46.0%	-56.3%	-42.3%	-49.8%	-52.5%	-38.9%	-34.9%	-41.9%	-50.0%	-47.9%	-61.4%	-39.2%	-43.3%	-46.6%	-51.1%	-34.0%	-38.6%	-44.3%	-49.4%	-51.4%	-56.7%	-54.9%	-54.0%	-61.2%	-61.9%	-61.5%	-53.1%	-51.1%	-44.5%	-44.0%	-40.9%	-41.7%	-41.9%	-42.9%	-37.4%	-31.8%
Debt ratio	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	6.4%	—	—	—	3.0%	5.8%	8.8%	10.3%	13.3%	15.6%	7.3%	9.0%	14.6%	13.7%	12.7%	15.7%	20.0%	21.3%	22.6%	27.9%	24.8%	19.1%	23.6%	20.9%	25.1%	21.8%	20.3%	22.0%	22.0%	20.6%	23.0%	22.4%	23.5%	22.0%	19.6%

EPS

Quarterly · US$

EPS US$-0.11

Show table：EPS

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q3	2011Q4	2011Q4	2011Q4	2012Q4	2012Q4	2012Q4	2012Q4	2013Q4	2013Q4	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1.59	—	-0.47	-0.40	-0.47	-0.51	-0.53	-0.55	-0.63	-0.58	-0.63	-0.63	-0.64	-0.50	-0.47	-0.46	-0.45	-0.42	-0.34	-0.28	-0.25	-0.36	-0.33	—	-0.40	-0.19	-0.11

Revenue & profit

Year-to-date · In mn (USD)

Revenue 171 mn Net income -126 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 916 mn Total liabilities 179 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -133 mn Investing -62.7 mn Financing 144 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -77.9% Net margin -74.0%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -40.4% ROA -31.8% Debt ratio 19.6%

EPS

Year-to-date · US$

EPS US$-0.30

Revenue & profit

Annual · In mn (USD)

Revenue 264 mn Net income -391 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0	0	0	0	—	—	—	—	—	164	264
Operating income	-27.8	-53.6	-92.9	-128	-207	-262	-343	-399	-461	-395	-403
Net income	-27.7	-52.9	-92.1	-124	-198	-260	-342	-396	-444	-372	-391

Balance sheet

Annual · In mn (USD)

Total assets 913 mn Total liabilities 215 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	104	170	149	475	316	636	508	479	308	457	443
Total assets	106	172	155	481	345	768	777	664	780	910	913
Current liabilities	1.63	4.97	9.89	14.4	39.1	54.9	89.2	91.5	110	122	138
Total liabilities	—	—	9.89	14.6	45.7	112	156	164	196	200	215
Equity	104	167	145	466	299	657	622	500	585	710	699

Cash flow

Annual · In mn (USD)

Operating -302 mn Investing 47.5 mn Financing 301 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-18.4	-32.7	-78.7	-101	-159	-205	-228	-293	-362	-353	-302
Investing	-71.2	8.89	58.7	-386	90.0	-318	0.13	256	-155	-96.4	47.5
Financing	78.3	96.9	58.7	424	6.13	576	239	190	463	391	301
Cash at period end	13.6	107	145	82.2	14.0	67.3	78.2	232	115	116	163

Profitability

Annual · %

Operating margin -153.1% Net margin -148.4%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	—	—	—	—	—	—	-240.9%	-153.1%
Net margin	—	—	—	—	—	—	—	—	—	-226.8%	-148.4%

Returns & leverage

Annual · %

ROE -55.5% ROA -42.9% Debt ratio 23.5%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-26.6%	-39.0%	-58.9%	-40.4%	-51.6%	-54.3%	-53.5%	-70.6%	-81.9%	-57.5%	-55.5%
ROA	-26.2%	-38.1%	-56.3%	-38.9%	-47.9%	-46.6%	-44.3%	-54.9%	-61.5%	-44.0%	-42.9%
Debt ratio	—	—	6.4%	3.0%	13.3%	14.6%	20.0%	24.8%	25.1%	22.0%	23.5%

EPS

Annual · US$

EPS US$-1.29

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	-2.22	-2.48	-1.88	-1.29	—

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read IOVANCE BIOTHERAPEUTICS, INC. (IOVA) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.